| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 46,005 | 46,065 | 17:16 | |
| 46,005 | 46,060 | 17:16 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 47,150 | 4.600 | |||
| 47,145 | 870 | |||
| 47,135 | 201 | |||
| 47,120 | 1.100 | |||
| 47,005 | 200 | |||
| 46,950 | 1.100 | |||
| 46,945 | 275 | |||
| 46,925 | 135 | |||
| 46,850 | 280 | |||
| 46,820 | 150 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/0qf.htm [/URL] | ||||
| 182 | 46,705 | |||
| 560 | 46,690 | |||
| 215 | 46,575 | |||
| 1.100 | 46,570 | |||
| 200 | 46,515 | |||
| 129 | 46,460 | |||
| 1.100 | 46,455 | |||
| 200 | 46,430 | |||
| 200 | 46,400 | |||
| 2 | 46,335 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 3.888 | 2,292 | 8.911 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 16:52:21 | 46,685 | 20 |
| 16:50:06 | 46,715 | 77 |
| 16:49:30 | 46,740 | 54 |
| 16:49:30 | 46,740 | 200 |
| 16:49:29 | 46,740 | 46 |
| 16:49:29 | 46,740 | 96 |
| 16:49:29 | 46,740 | 200 |
| 16:49:28 | 46,740 | 127 |
| 16:49:28 | 46,740 | 115 |
| 16:49:24 | 46,740 | 200 |
| 16:49:24 | 46,740 | 1 |
| 16:49:24 | 46,740 | 182 |
| 16:49:24 | 46,740 | 2 |
| 16:49:24 | 46,740 | 171 |
| 16:49:24 | 46,740 | 75 |
| 16:49:24 | 46,740 | 2 |
| 16:49:24 | 46,740 | 167 |
| 16:49:24 | 46,740 | 333 |
| 16:30:57 | 47,110 | 170 |
| 16:24:07 | 46,920 | 76 |
| Tagesumsatz Xetra | +1,300 +2,86 % | 13.194 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17:10 | Sanofi touts tolerability of COVID shot Nuvaxovid in head-to-head trial vs. Moderna's mNexspike | 4 | FiercePharma | ||
| 13:05 | Moderna's Quarterly Earnings Preview: What You Need to Know | 9 | Barchart.com | ||
| So | Sanofi's Nuvaxovid Shows Superior Tolerability Over Moderna's MNEXSPIKE In COMPARE Study | 658 | AFX News | PARIS (dpa-AFX) - Sanofi's (SNY, SNYNF,SAN.PA) protein-based COVID-19 vaccine, Nuvaxovid (NVX-CoV2705), demonstrated a significantly better tolerability profile compared to Moderna's latest... ► Artikel lesen | |
| MODERNA Aktie jetzt für 0€ handeln | |||||
| Fr | Moderna-Krebstherapie erzielt 83 % Ansprechrate bei Melanom-Studie | 48 | Investing.com Deutsch | ||
| Fr | Moderna's melanoma therapy shows 83% response rate in trial | 19 | Investing.com |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 13:34 | Biogen Inc.: Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region | GlobeNewswire (Europe) | With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one ownerAdvancing felzartamab - a CD38-directed... ► Artikel lesen | |
| 15:27 | Depot: AtaiBeckley hebt ab: Marvell: Alphabet bestellt, Kailera: Starkes IPO & Siemens: Macht es wie Nvidia | Markus Weingran | Siemens steigt beim Lithium-Projekt von Vulcan Energy ein. Zum einen wird der Konzern Minderheitsaktionär, zum anderen sichert man sich einen Auftrag in Höhe von 40 Millionen €. Nvidia macht diesen... ► Artikel lesen | |
| 13:10 | Trader-Interview mit Bastian Galuschka SAP, BASF, ATAIBeckley, Kalvista, MarvellTechnology, Echostar | LS-X Trader | In dieser Ausgabe des Trader-Interviews analysieren Lothar Albert und Bastian Galuschka die aktuelle Börsenlage und beleuchten ausgewählte Einzelwerte mit speziellem Fokus auf technische Signale, fundamentale... ► Artikel lesen | |
| 14:15 | EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Group (EN) | EQS Voting Rights Announcement: Evotec SE
Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen | |
| 14:27 | EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Group (EN) | EQS Voting Rights Announcement: Evotec SE
Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide... ► Artikel lesen |